Pharma, Startups

San Diego biotech Glycoregimmune raises $4.3 million for natural killer T cell-based therapy

San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that […]

San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease.

Natural killer T cells are a sort of heterogenous variety of immune cell; the company says:

NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.

The immunotherapy biotech just raised $4.3 million, according to a regulatory filing. The research comes from Torrey Pines Institute for Molecular Studies.

Its lead program, the oral drug GRI-0621, is in the midst of early clinical studies among chronic liver disease patients.

Shares0
Shares0